Amgen, ImmunoGen deal

ImmunoGen received a $1 million milestone payment from Amgen under a 2000 deal granting Abgenix Inc. rights to ImmunoGen's maytansinoid Targeted Antibody Payload (TAP) technology. Amgen acquired Abgenix in 2006. The payment was triggered by FDA's acceptance of Amgen's IND submission for an undisclosed anticancer compound that utilizes TAP. TAP technology uses antibodies to deliver antitumor agents to specific targets. In 2009, Amgen exercised two options for exclusive, worldwide rights to TAP technology against undisclosed cancer targets (see BioCentury, Sept. 11, 2000; Sept. 21, 2009 & Dec. 7, 2009). ...